Trials / Unknown
UnknownNCT05372120
A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II clinical trial in treated patients with advanced solid tumors with FGF/FGFR gene alterations. The purpose of this study is to evaluate the efficacy and safety of ICP-192.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-192 | ICP-192 is a round, uncoated tablet, 4mg, 5mg. It is administered orally at the dose of 20 mg/day from day 1 to day 21 of each cycle until progression |
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
- First posted
- 2022-05-12
- Last updated
- 2023-01-04
Locations
37 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05372120. Inclusion in this directory is not an endorsement.